Scilex Holding Co is an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain. The company markets three FDA approved products ZTlido for postherpetic neuralgia ELYXYB for acute migraine and GLOPERBA for gout prophylaxis. It also has a pipeline of product candidates including SEMDEXA for sciatica SP-103 for acute pain and SP-104 for fibromyalgia.
Revenue is…
Scilex Holding Co is an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain. The company markets three FDA approved products ZTlido for postherpetic neuralgia ELYXYB for acute migraine and GLOPERBA for gout prophylaxis. It also has a pipeline of product candidates including SEMDEXA for sciatica SP-103 for acute pain and SP-104 for fibromyalgia.
Revenue is generated primarily from sales of its approved products ZTlido ELYXYB and GLOPERBA to wholesalers pharmacies and health care providers. The company also earns revenue from contract manufacturing services and royalties related to its licensed products. While the firm has adopted a cryptocurrency treasury strategy it does not currently treat digital assets as a primary source of operating revenue.
Within the pain management market the company occupies a niche focused on non opioid therapies that address unmet needs in neuropathic pain migraine and gout. Its lead product ZTlido competes against branded lidocaine patches such as Lidoderm and generic versions from manufacturers like Teva Mylan and Par Pharmaceutical. ELYXYB faces competition from other migraine treatments including NSAIDs triptans and CGRP inhibitors. GLOPERBA is the only FDA approved liquid colchicine product and competes with generic colchicine formulations and uric acid lowering agents such as allopurinol. The company’s competitive advantages stem from its proprietary drug delivery technology its strong patent portfolio and its ability to secure formulary placement with major payers.
The company sells its products through a network of national and regional wholesalers including McKesson Cardinal Health and AmerisourceBergen. These distributors supply retail chains such as CVS Walgreens Rite Aid and independent pharmacies. Formulary coverage has been secured with major payers including CVS Caremark Aetna Cigna Express Scripts United Healthcare Optum Rx Anthem BCBS and various state Medicaid programs.
Sector:HealthcareSector rationaleThe company's primary revenue is generated from the sale of FDA-approved pharmaceutical products (ZTlido, ELYXYB, and GLOPERBA) to wholesalers, pharmacies, and healthcare providers. It also earns revenue from contract manufacturing services and royalties related to these medical products, placing it squarely within the Healthcare sector.Industries:PharmaceuticalsHealthcarePrimaryScilex Holding develops and markets branded prescription drugs for pain management, specifically ZTlido for postherpetic neuralgia, ELYXYB for acute migraine, and GLOPERBA for gout prophylaxis. Revenue is generated from the sales of these branded pharmaceutical products to wholesalers and healthcare providers.Contract ManufacturingHealthcareSecondaryThe company explicitly earns revenue from providing contract manufacturing services in addition to its own product sales.Classified using BQ-MICSCIK: 0001820190